FDA to appoint permanent heads of CBER and CDER alongside new commissioner

The FDA is preparing to announce a series of senior leadership changes concurrent with the appointment of a new commissioner.

Among the planned announcements are permanent appointments for the heads of the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER).

The moves are intended to provide stable leadership for the two major regulatory centers as the agency transitions to new top level management.

Sources familiar with the planning said the announcements will be made shortly after the commissioner is named, signaling a coordinated effort to solidify the FDA's leadership structure.